Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
ZEO ScientifiX signed a definitive strategic agreement with Pluri to build a combined U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity. In exchange for rights to Pluri's manufacturing technology, ZEO will issue shares representing 50% of its outstanding common stock at closing, and Pluri will gain exclusive U.S. rights to the Cellav aesthetics line through ZEO's physician network.
Key figures
- Pluri patents
- over 200
- Expected closing
- Q4 2026
- Pluri post closing ownership
- 50%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.